Royalty Pharma plc Class A Ordinary Shares Earnings Dividend

Royalty Pharma plc Class A Ordinary Shares’s revenue jumped 16.5% since last year same period to $674.14Mn in the Q2 2026. On a quarterly growth basis, Royalty Pharma plc Class A Ordinary Shares has generated 6.91% jump in its revenue since last 3-months.

Royalty Pharma plc Class A Ordinary Shares’s net profit fell -40.74% since last year same period to $17.88Mn in the Q2 2026. On a quarterly growth basis, Royalty Pharma plc Class A Ordinary Shares has generated -93.94% fall in its net profits since last 3-months.

Royalty Pharma plc Class A Ordinary Shares’s net profit margin fell -49.13% since last year same period to 2.65% in the Q2 2026. On a quarterly growth basis, Royalty Pharma plc Class A Ordinary Shares has generated -94.33% fall in its net profit margins since last 3-months.

Royalty Pharma plc Class A Ordinary Shares’s earning per share (EPS) estimates for the current quarter stand at 1.27 - a 7.63% jump from last quarter’s estimates.

Royalty Pharma plc Class A Ordinary Shares’s earning per share (EPS) estimates for the current year stand at 1.27.

Royalty Pharma plc Class A Ordinary Shares’s earning per share (EPS) jumped 15.79% since last year same period to 1.32 in the Q2 2026. This indicates that the Royalty Pharma plc Class A Ordinary Shares has generated 15.79% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Royalty Pharma plc Class A Ordinary Shares declared 0.24 dividend per share during the earnings announcement for Q2 2026.